Special Drug Use - Results Survey Of Evaluating Safety And Effectiveness Of RINVOQ In Patients With Rheumatoid Arthritis
Latest Information Update: 05 Mar 2025
At a glance
- Drugs Upadacitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors AbbVie
Most Recent Events
- 03 Dec 2024 Planned End Date changed from 15 Aug 2025 to 1 Aug 2025.
- 03 Dec 2024 Planned primary completion date changed from 15 Aug 2025 to 1 Aug 2025.
- 24 Apr 2024 Planned End Date changed from 30 Apr 2024 to 15 Aug 2025.